Betabisâ„¢ 2.5: Each film-coated tablet contains Bisoprolol Fumarate USP 2.5 mg.
Betabisâ„¢ 5: Each film-coated tablet contains Bisoprolol Fumarate USP 5 mg.
Betabisâ„¢ 10: Each film-coated tablet contains Bisoprolol Fumarate USP 10 mg.
Bisoprolol is the most potent $\beta_1$ -selective $\beta$ -blocker. It has the highest level of $\beta_1$ -selectivity and by blocking the heart’s $\beta_1$ adrenergic receptors it reduces heart rate & force of contraction of the heart and thus lowers blood pressure.
Route of Administration: Orally.
In Hypertension: The dose of Betabisâ„¢ must be individualized to the needs of the patient. The usual starting dose is 5 mg once daily. In some patients, 2.5 mg may be an appropriate starting dose. If the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily.
Patients with Renal or Hepatic Impairment: In patients with hepatic impairment (hepatitis or cirrhosis) or renal dysfunction (creatinine clearance <40 mL/min), the initial daily dose should be 2.5 mg and caution should be used in dose-titration. Since limited data suggest that Bisoprolol is not dialyzable, drug replacement is not necessary in patients undergoing dialysis.
Geriatric Patients: It is not necessary to adjust the dose in the elderly, unless there is also significant renal or hepatic dysfunction.
In Heart Failure: Initially 1.25 mg once daily (in the morning) for 1 week; then, if well tolerated, can be increased to 2.5 mg once daily for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4 weeks, then 7.5 mg once daily for 4 weeks, then 10 mg once daily; max. 10 mg daily.
Or as Directed by the Physician.:
With Medicine: Bisoprolol should not be combined with other $\beta$ -blocking agents. Patients receiving catecholamine-depleting drugs (e.g. Reserpine or Guanethidine) should be closely monitored. In patients receiving concurrent therapy with Clonidine, if therapy is to be discontinued, it is suggested that Bisoprolol be discontinued for several days before the withdrawal of Clonidine. Bisoprolol should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (e.g. Verapamil, Diltiazem) or antiarrhythmic agents (e.g. Disopyramide) are used concurrently. Concurrent use of Rifampin increases the metabolic clearance of Bisoprolol resulting in a shortened elimination half-life of Bisoprolol.
With food & others: No interaction with foods.
Overdose:
The most common signs expected with overdose (max. 2000 mg) of a $\beta$ -blocker are bradycardia, hypotension, congestive heart failure, bronchospasm and hypoglycemia.
Safety and effectiveness have not been established in children.
Impaired renal or hepatic function: Use with caution adjusting the dose of Bisoprolol in patients with renal or hepatic impairment.
Risk of anaphylactic reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens, caution should be exercised. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
Store below 30°C temperature & dry place, protected from light. Keep all medicines out of reach of children.